I do not like sidekicks like this. Many preclinical studies are done in big indications by ATH, but not published and FA is small and even smaller than MSA as an indication. The company classifies this as "no price sensitive". With this small market capital positive "price-sensitive" news is needed. Most likely Dr. Pall initiated this study and I think ATH could live even without this until it can afford side-kicks in FA.
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-6
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.5¢ |
Change
0.001(25.0%) |
Mkt cap ! $26.22M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.5¢ | 0.5¢ | $10.54K | 2.185M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 59 | 83226460 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 20397608 | 18 |
View Market Depth
| Last trade - 10.13am 07/06/2024 (20 minute delay) ? |
| ATH (ASX) Chart |